David I. Gwynne
Corporate Officer/Principal bei NeuroHealing Pharmaceuticals, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Neal M. Farber | M | - |
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | - |
Mark Leuchtenberger | M | 67 |
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | 11 Jahre |
Elkan R. Gamzu | M | 81 |
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | - |
Joshua D. Hamermesh | M | 51 |
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | 10 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Daniel Katzman | M | - |
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | - |
Esteban Fridman | M | - |
NeuroHealing Pharmaceuticals, Inc.
NeuroHealing Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeuroHealing Pharmaceuticals, Inc. develops drug therapies for the post-acute and chronic neuro-rehabilitation patients. Its products include NH001, a dopaminergic agent to help post traumatic brain injury patients to emerge from a coma, vegetative, or minimally consciousness state, NH004, a treatment for the social debilitating condition of sialorrhea, a non-motor complaint of Parkinson's disease patients and NH02D, an orally administered drug for on-demand treatment of premature ejaculation, a male sexual disorder affecting sexually active men. The company was founded by Esteban Fridman and Daniel Katzman in 2003 and is headquartered in Waban, MA. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 6 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- David I. Gwynne
- Persönliches Netzwerk